axicabtagene ciloleucel
daiichi sankyo,gilead
['axi-cel', 'zuma-5', 'nhl']
jtcc's collaborated in the zuma-5 study of axi-cel in patients with r/r inhl (fl and mzl). outcomes after 3 or more years confirm durable responses in patients with r/r inhl, with improved survival in patients with mzl. #ash2022 #cart 
John Theurer Cancer Center @HackensackUMC is among the nation's top cancer hospitals with 14 specialized divisions providing the most advanced care possible.